Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.04% Nasdaq Up0.55%

Neurocrine Biosciences Inc. (NBIX)

-NasdaqGS
13.77 Down 0.01(0.07%) 3:09PM EDT - Nasdaq Real Time Price
Get the big picture on all your investments.
ProfileGet Profile for:
Neurocrine Biosciences Inc.
12780 El Camino Real
San Diego, CA 92130
United States - Map
Phone: 858-617-7600
Fax: 858-617-7601
Website: http://www.neurocrine.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:81

Business Summary 

Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company’s products in clinical development stage include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for tourette syndrome schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men’s and women’s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Key Statistics


Company Websites 
Home Page
Investor Relations
Employment
Search Yahoo! for:
More on Neurocrine Biosciences Inc.

Corporate Governance 
Neurocrine Biosciences Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 7; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Kevin C. Gorman Ph.D., 56
Chief Exec. Officer, Pres and Director
758.00K0.00
Mr. Timothy P. Coughlin , 47
Chief Financial Officer, Principal Accounting Officer and VP
542.00K107.00K
Dr. Dimitri E. Grigoriadis Ph.D., 56
Chief Research Officer
448.00K743.00K
Dr. Haig P. Bozigian Ph.D., 56
Chief Devel. Officer
487.00K749.00K
Dr. Christopher F. O'Brien M.D., 57
Chief Medical Officer and Sr. VP
591.00K441.00K
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders